| Website | archventure.com |
| Phone | 773 380 6600 |
| Employees | |
| Founded | 1986 |
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.
ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors.
| Company | Date | Round | Size | Participants |
| Innovalight | 10/09 | Unattributed | $15M | 7 |
| Shocking Technologies | 8/09 | Series B | $10M | 3 |
| Limerick BioPharma | 7/09 | Series C | $15M | 3 |
| Semprius | 6/09 | Series B | $6.4M | 5 |
| Elixir Pharmaceuticals | 5/09 | Series D | $12M | 5 |
| Lycera | 5/09 | Series A | $36M | 4 |
| Qwell Pharmaceuticals | 1/09 | Series A | $7M | 2 |
| Sapphire Energy | 9/08 | Series D | $35M | 2 |
| Limerick BioPharma | 6/08 | Unattributed | $15.2M | 3 |
| Sapphire Energy | 5/08 | Series C | $50M | 2 |
| Kythera Biopharmaceuticals | 5/08 | Series C | $30M | 9 |
| Univa UD | 5/08 | Series B | $8M | 5 |
| KOTURA | 2/08 | Series C | $10M | 5 |
| MediaPhy | 2/08 | Unattributed | $7M | 2 |
| Xtera Communications Inc. | 8/07 | Unattributed | $52M | 3 |
| Shocking Technologies | 4/07 | Series A | $7M | 2 |
| Elixir Pharmaceuticals | 11/06 | Series C | $46M | 6 |
| Univa UD | 8/05 | Series A | $8M | 4 |
